Myocarditis Following a Third BNT162b2 Vaccination Dose in Military Recruits in Israel

doi:10.1001/jama.2022.4425

. 2022 Apr 26;327(16):1611-1612.

doi: 10.1001/jama.2022.4425.

Myocarditis Following a Third BNT162b2 Vaccination Dose in Military Recruits in Israel

Limor Friedensohn¹, Dan Levin¹, Maggie Fadlon-Derai¹, Liron Gershovitz¹, Noam Fink¹, Elon Glassberg¹, Barak Gordon¹

Affiliations

PMID: 35297962
PMCID: PMC8931670
DOI: 10.1001/jama.2022.4425

Myocarditis Following a Third BNT162b2 Vaccination Dose in Military Recruits in Israel

Limor Friedensohn et al. JAMA. 2022.

. 2022 Apr 26;327(16):1611-1612.

doi: 10.1001/jama.2022.4425.

Authors

Limor Friedensohn¹, Dan Levin¹, Maggie Fadlon-Derai¹, Liron Gershovitz¹, Noam Fink¹, Elon Glassberg¹, Barak Gordon¹

Affiliation

¹ Medical Corps, Israel Defense Forces, Israel.

PMID: 35297962
PMCID: PMC8931670
DOI: 10.1001/jama.2022.4425

Abstract

This study assessed whether a third vaccine dose was associated with the risk of myocarditis among military personnel in Israel.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Cited by

Influence of mRNA Covid-19 vaccine dosing interval on the risk of myocarditis.
Le Vu S, Bertrand M, Semenzato L, Jabagi MJ, Botton J, Drouin J, Weill A, Dray-Spira R, Zureik M. Le Vu S, et al. Nat Commun. 2024 Sep 5;15(1):7745. doi: 10.1038/s41467-024-52038-6. Nat Commun. 2024. PMID: 39232036 Free PMC article.
How denialist amplification spread COVID misinformation and undermined the credibility of public health science.
Morris RD. Morris RD. J Public Health Policy. 2024 Mar;45(1):114-125. doi: 10.1057/s41271-023-00451-4. Epub 2024 Feb 22. J Public Health Policy. 2024. PMID: 38388891 Review.
Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity.
Muñoz-Alía MÁ, Nace RA, Balakrishnan B, Zhang L, Packiriswamy N, Singh G, Warang P, Mena I, Narjari R, Vandergaast R, Peng K-W, García-Sastre A, Schotsaert M, Russell SJ. Muñoz-Alía MÁ, et al. mBio. 2024 Feb 14;15(2):e0292823. doi: 10.1128/mbio.02928-23. Epub 2024 Jan 9. mBio. 2024. PMID: 38193729 Free PMC article.
Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a case-control study.
Fan M, Lai FTT, Cheng FWT, Tsie NTY, Li X, Wan EYF, Wong CKH, Chan EWY, Yiu KH, Wong ICK, Chui CSL. Fan M, et al. Lancet Reg Health West Pac. 2023 Jun;35:100745. doi: 10.1016/j.lanwpc.2023.100745. Epub 2023 Mar 25. Lancet Reg Health West Pac. 2023. PMID: 37360861 Free PMC article.
Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
Stowe J, Miller E, Andrews N, Whitaker HJ. Stowe J, et al. PLoS Med. 2023 Jun 7;20(6):e1004245. doi: 10.1371/journal.pmed.1004245. eCollection 2023 Jun. PLoS Med. 2023. PMID: 37285378 Free PMC article.

See all "Cited by" articles

References

1. Bar-On YM, Goldberg Y, Mandel M, et al. . Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N Engl J Med. 2021;385(15):1393-1400. doi:10.1056/NEJMoa2114255 - DOI - PMC - PubMed
1. Shay DK, Shimabukuro TT, DeStefano F. Myocarditis occurring after immunization with mRNA-based COVID-19 vaccines. JAMA Cardiol. 2021;6(10):1115-1117. doi:10.1001/jamacardio.2021.2821 - DOI - PubMed
1. Oster ME, Shay DK, Su JR, et al. . Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022;327(4):331-340. doi:10.1001/jama.2021.24110 - DOI - PMC - PubMed
1. Levin D, Shimon G, Fadlon-Derai M, et al. . Myocarditis following COVID-19 vaccination: a case series. Vaccine. 2021;39(42):6195-6200. doi:10.1016/j.vaccine.2021.09.004 - DOI - PMC - PubMed
1. Mevorach D, Anis E, Cedar N, et al. . Myocarditis after BNT162b2 mRNA vaccine against COVID-19 in Israel. N Engl J Med. 2021;385(23):2140-2149. doi:10.1056/NEJMoa2109730 - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Bar-On YM, Goldberg Y, Mandel M, et al. . Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N Engl J Med. 2021;385(15):1393-1400. doi:10.1056/NEJMoa2114255 - DOI - PMC - PubMed

[2] Bar-On YM, Goldberg Y, Mandel M, et al. . Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N Engl J Med. 2021;385(15):1393-1400. doi:10.1056/NEJMoa2114255 - DOI - PMC - PubMed

[3] Shay DK, Shimabukuro TT, DeStefano F. Myocarditis occurring after immunization with mRNA-based COVID-19 vaccines. JAMA Cardiol. 2021;6(10):1115-1117. doi:10.1001/jamacardio.2021.2821 - DOI - PubMed

[4] Shay DK, Shimabukuro TT, DeStefano F. Myocarditis occurring after immunization with mRNA-based COVID-19 vaccines. JAMA Cardiol. 2021;6(10):1115-1117. doi:10.1001/jamacardio.2021.2821 - DOI - PubMed

[5] Oster ME, Shay DK, Su JR, et al. . Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022;327(4):331-340. doi:10.1001/jama.2021.24110 - DOI - PMC - PubMed

[6] Oster ME, Shay DK, Su JR, et al. . Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022;327(4):331-340. doi:10.1001/jama.2021.24110 - DOI - PMC - PubMed

[7] Levin D, Shimon G, Fadlon-Derai M, et al. . Myocarditis following COVID-19 vaccination: a case series. Vaccine. 2021;39(42):6195-6200. doi:10.1016/j.vaccine.2021.09.004 - DOI - PMC - PubMed

[8] Levin D, Shimon G, Fadlon-Derai M, et al. . Myocarditis following COVID-19 vaccination: a case series. Vaccine. 2021;39(42):6195-6200. doi:10.1016/j.vaccine.2021.09.004 - DOI - PMC - PubMed

[9] Mevorach D, Anis E, Cedar N, et al. . Myocarditis after BNT162b2 mRNA vaccine against COVID-19 in Israel. N Engl J Med. 2021;385(23):2140-2149. doi:10.1056/NEJMoa2109730 - DOI - PMC - PubMed

[10] Mevorach D, Anis E, Cedar N, et al. . Myocarditis after BNT162b2 mRNA vaccine against COVID-19 in Israel. N Engl J Med. 2021;385(23):2140-2149. doi:10.1056/NEJMoa2109730 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Myocarditis Following a Third BNT162b2 Vaccination Dose in Military Recruits in Israel

Affiliation

Myocarditis Following a Third BNT162b2 Vaccination Dose in Military Recruits in Israel

Authors

Affiliation

Abstract

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Abstract

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical